False Hope

"False Hope is a must-read- a cautionary tale of what happens when our hopes for a medical breakthrough lead us to press for access to it too soon. This book is a rare treat. It is chock full of detail yet a real page turner. Whether you are someone in a position to help prevent similar mistakes in the future, a student seeking to understand the complexities of advances in health sciences, or simply an interested observer of human nature,FalseHope is a great story."--Kay Dickersin, Director, Center for Clinical Trials at Johns Hopkins Bloomberg School of Public Health"This fascinating and important book should be a must-read for all who are professionally associated with health care. The story reaffirms the importance of randomized controlled trials, and the dangers of relying on patient panic, physician enthusiasm, the media, litigation, and money."--Alain Enthoven, Marriner S. Eccles Professor of Public and Private Management(Emeritus), Graduate School of Business, Stanford University"False Hope is an in-depth study of one of the many new cancer therapies that have offered early promise and eventually failed. An emotionally wrenching process, it can be very confusing for cancer patients who pin their hopes on these promising therapies. This book provides invaluable insight into the many factors at play when a new therapy comes on the scene."--I. Craig Henderson, Adjunct Professor of Medicine, University of California, SanFrancisco"The story is not only fascinating, like a complex mystery novel, but many of the players in academia, industry and private practice are well known to most of us...I highly recommend the book in the hope that through its lessons we can postpone a recurrence for a long time."--Oncology Times"False Hope shows how painfully obvious, in retrospect, is the case for high standards of evidence when it comes to medical decisionmaking."--Lancet"The old proverb says that 'history is written by the winners,' and this book is no exception...This piece of medical history is a sobering reminder that although some new therapies pan out, many do not, and caveat emptor is not a satisfactory approach to choosing health care."--New England Journal of Medicine"False Hope is a meticulously researched case study of clinical medicine 'jumping the gun' by introducing an expensive and toxic procedure in response to the desperation of women (and their families and physicians) with metastatic and high risk early breast cancer...I recommend this book to all Oncology health professionals and anyone with an interest in health technology assessment of new medical procedures. It is a surprisingly 'goodread.'"--New Zealand Medical Journal"The authors push beyond what is widely known about the use of the procedure in an organized and effective fashion. Chapters focus on the emergence of HDC/ABMT as a treatment for cancer, the various litigation strategies used by those representing patients seeking coverage of HDC/ABMT from insurers, and the role of entrepreneurial oncology (that is, those who profited from the procedure) in rapidly expanding its use."--Health Affairs"This book is well written and researched. It will be of interest to all professionals and organizations involved in the trials of new treatments and drugs."--Oncology News"This story of the convergence of medical innovation, social and economical pressures in health care, the women's movement, and media forces is mesmerizing...Members of all healthcare professions, administrators who offer or anticipate offering a program of clinical cancer research, and the general public will benefit from reading this book."--Oncology Nursing Forum"False Hope is a must-read- a cautionary tale of what happens when our hopes for a medical breakthrough lead us to press for access to it too soon. This book is a rare treat. It is chock full of detail yet a real page turner. Whether you are someone in a position to help prevent similar mistakes in the future, a student seeking to understand the complexities of advances in health sciences, or simply an interested observer of human nature,FalseHope is a great story."--Kay Dickersin, Director, Center for Clinical Trials at Johns Hopkins Bloomberg School of Public Health"This fascinating and important book should be a must-read for all who are professionally associated with health care. The story reaffirms the importance of randomized controlled trials, and the dangers of relying on patient panic, physician enthusiasm, the media, litigation, and money."--Alain Enthoven, Marriner S. Eccles Professor of Public and Private Management(Emeritus), Graduate School of Business, Stanford University"False Hope is an in-depth study of one of the many new cancer therapies that have offered early promise and eventually failed. An emotionally wrenching process, it can be very confusing for cancer patients who pin their hopes on these promising therapies. This book provides invaluable insight into the many factors at play when a new therapy comes on the scene."--I. Craig Henderson, Adjunct Professor of Medicine, University of California, SanFrancisco"The story is not only fascinating, like a complex mystery novel, but many of the players in academia, industry and private practice are well known to most of us...I highly recommend the book in the hope that through its lessons we can postpone a recurrence for a long time."--Oncology Times"False Hope shows how painfully obvious, in retrospect, is the case for high standards of evidence when it comes to medical decisionmaking."--Lancet"The old proverb says that 'history is written by the winners,' and this book is no exception...This piece of medical history is a sobering reminder that although some new therapies pan out, many do not, and caveat emptor is not a satisfactory approach to choosing health care."--New England Journal of Medicine"False Hope is a meticulously researched case study of clinical medicine 'jumping the gun' by introducing an expensive and toxic procedure in response to the desperation of women (and their families and physicians) with metastatic and high risk early breast cancer...I recommend this book to all Oncology health professionals and anyone with an interest in health technology assessment of new medical procedures. It is a surprisingly 'goodread.'"--New Zealand Medical Journal"The authors push beyond what is widely known about the use of the procedure in an organized and effective fashion. Chapters focus on the emergence of HDC/ABMT as a treatment for cancer, the various litigation strategies used by those representing patients seeking coverage of HDC/ABMT from insurers, and the role of entrepreneurial oncology (that is, those who profited from the procedure) in rapidly expanding its use."--Health Affairs"This book is well written and researched. It will be of interest to all professionals and organizations involved in the trials of new treatments and drugs."--Oncology News"This story of the convergence of medical innovation, social and economical pressures in health care, the women's movement, and media forces is mesmerizing...Members of all healthcare professions, administrators who offer or anticipate offering a program of clinical cancer research, and the general public will benefit from reading this book."--Oncology Nursing Forum

• PART I: INITIAL CONDITIONS ; PART II: DRIVERS OF CLINICAL USE ; PART III: THE STRUGGLE OF EVIDENCE-BASED MEDICINE ; PART IV: THE SIGNIFICANCE OF THE STORY